Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015;16(5):645-7.
doi: 10.1080/15384047.2015.1030553.

When are signal transduction targeted therapies acting as immunotherapy?

Keith T Flaherty  1
Affiliations
Comment

When are signal transduction targeted therapies acting as immunotherapy?

Keith T Flaherty. Cancer Biol Ther. 2015.
No abstract available

Keywords: BRAF inhibitor; interleukin-2; ipilimumab; melanoma; synergy.

PubMed Disclaimer

Comment on

  • Inhibition of mutated, activated BRAF in metastatic melanoma.
    Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Flaherty KT, et al. N Engl J Med. 2010 Aug 26;363(9):809-19. doi: 10.1056/NEJMoa1002011. N Engl J Med. 2010. PMID: 20818844 Free PMC article. Clinical Trial.

References

    1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711–23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466 - DOI - PMC - PubMed
    1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al.. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320–30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082 - DOI - PubMed
    1. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, et al.. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014; 371:1877–88; PMID:25265492; http://dx.doi.org/10.1056/NEJMoa1406037 - DOI - PubMed
    1. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, et al.. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013; 19:1225–31; PMID:23307859; http://dx.doi.org/10.1158/1078-0432.CCR-12-1630 - DOI - PMC - PubMed
    1. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford RF, Hersey P, Scolyer RA. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18:1386–94; PMID:22156613; http://dx.doi.org/10.1158/1078-0432.CCR-11-2479 - DOI - PubMed

MeSH terms